Windtree Therapeutics
WINT
WINT was delisted on the 20th of August, 2025.
9 hedge funds and large institutions have $2.72M invested in Windtree Therapeutics in 2021 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
50% more funds holding
Funds holding: 6 → 9 (+3)
0% more ownership
Funds ownership: 0% → 0% (+0%)
18% less capital invested
Capital invested by funds: $3.33M → $2.72M (-$616K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.3M |
| 2 |
KC
Kepos Capital
New York
|
+$433K |
| 3 |
AAA
Affinity Asset Advisors
New York
|
+$216K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$216K |
| 5 |
Envestnet Asset Management
Chicago,
Illinois
|
+$216K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FWM
Frontier Wealth Management
Kansas City,
Missouri
|
-$308K |
| 2 |
Northern Trust
Chicago,
Illinois
|
-$216K |
| 3 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$95K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$19K |
| 5 |
TI
tru Independence
Portland,
Oregon
|
-$308 |
WINT Hedge Fund Activity: Q1 2021 in Review
9 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Windtree Therapeutics (WINT) for Q1 2021, worth a combined $2.72M — down 18% from $3.33M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new WINT positions and 2 closed out — a net gain of 3 holders — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.3M. The largest seller was Frontier Wealth Management, exiting entirely with an estimated $308K sold.
- 9 institutional investors held Windtree Therapeutics (WINT) as of Q1 2021, up from 6 in Q4 2020.
- Funds reported $2.72M of Windtree Therapeutics stock for Q1 2021, down 18% quarter-over-quarter.
- 5 funds opened new Windtree Therapeutics positions in Q1 2021 and 2 closed out, a net change of +3 holders.
- The largest Windtree Therapeutics buyer in Q1 2021 was Vanguard Group, an estimated $1.3M added.
- The largest Windtree Therapeutics seller in Q1 2021 was Frontier Wealth Management, an estimated $308K sold.
Based on aggregated 13F filings for Q1 2021.